GREM1 has been suggested to be a modulator of mesangial cell proliferation and epithelial–mesenchymal transdifferentiation in diabetes and has been shown to have increased expression in various diabetic nephropathy models as well as being involved in the pathophysiology of progressive renal fibrogenetic diseases [26, 27]. Here, GREM1 is linked to diabetes mellitus.